TRANSTHYRETIN AMYLOIDOSIS
Clinical trials for TRANSTHYRETIN AMYLOIDOSIS explained in plain language.
Never miss a new study
Get alerted when new TRANSTHYRETIN AMYLOIDOSIS trials appear
Sign up with your email to follow new studies for TRANSTHYRETIN AMYLOIDOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Breakthrough trial aims to stop devastating genetic disease before it starts
Prevention Recruiting nowThis study is testing whether a new drug called acoramidis can prevent or delay heart and nerve damage in people who carry a gene for a serious disease but don't yet have symptoms. About 582 adults aged 18-75 with the genetic risk will receive either the drug or a placebo to see …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE3 • Sponsor: Eidos Therapeutics, a BridgeBio company • Aim: Prevention
Last updated Mar 23, 2026 15:15 UTC
-
First look: tracking rare Drug's effects on pregnant patients and babies
Knowledge-focused Recruiting nowThis study aims to understand the safety of the medication eplontersen when taken during pregnancy or while breastfeeding. Researchers will collect and review health reports from pregnant or breastfeeding individuals who are taking the drug for a rare disease called transthyretin…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 03, 2026 14:42 UTC
-
New scan aims to map deadly protein buildup in the heart
Knowledge-focused Recruiting nowThis study is testing a new imaging tracer called Iodine-124 evuzumitide (AT-01) to see if it can create better pictures of where harmful amyloid proteins build up in the body, especially in the heart. Researchers will scan 150 patients with systemic amyloidosis using PET/MRI or …
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:34 UTC
-
Massive global study tracks rare heart and nerve disease
Knowledge-focused Recruiting nowThis study aims to observe and document the real-world experiences of people living with ATTR amyloidosis, a rare disease that can damage the heart and nerves. It will follow at least 1850 patients for 3 to 7 years, collecting information from their regular medical visits to unde…
Matched conditions: TRANSTHYRETIN AMYLOIDOSIS
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:28 UTC